Basic Information
| LncRNA/CircRNA Name | CYTOR |
| Synonyms | cytoskeleton regulator RNA |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Tamoxifen | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | RT-qPCR, Western blotting, Dual luciferase reporter assay |
| Sample | tumor and normal tissues,breast cancer cell lines MCF7 |
| Expression Pattern | up-regulated |
| Function Description | Through regulation of miR-125a-5p, CYTOR elevated serum response factor (SRF) expression and activated Hippo and mitogen associated protein kinase signaling pathways to promote breast cancer cell survival upon tamoxifen treatment.In the collected tumor tissues of breast cancer in the present study, high expression of CYTOR was detected in tissues from patients with no response to tamoxifen compared with those from patients who were not treated with tamoxifen. A positive correlation between CYTOR and SRF mRNA expression was observed in tissues collected from patients with breast cancer. |
| Pubmed ID | 31894257 |
| Year | 2020 |
| Title | lncRNA CYTOR Promotes Tamoxifen Resistance in Breast Cancer Cells via Sponging miR-125a-5p |
External Links
| Links for CYTOR | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |